A Risk-Based Approach to Setting Sterile Filtration Bioburden Limits
|
|
- Alexia Farmer
- 6 years ago
- Views:
Transcription
1 EBE Psitin Paper Draft: Final: Authr: EBE BiManufacturing WG Date: 13/09/2016 EBE Psitin Paper: A Risk-Based Apprach t Setting Sterile Filtratin Biburden Limits Executive Summary The ratinale behind the EMA recmmended biburden limit befre sterile filtratin f NMT 10 CFU / 100 ml (EMA Guidelines f 1996 (1), 2012 (2) and Draft EMA Guideline 2016 (3)) has n clear rigin. The limit has been taken frm the pharmacpeial specificatin fr water fr injectin t prduce bulk, but has n scientific basis when applied t drug prduct. Overall, we wuld instead prpse a "Risk-based Apprach" t biburden cntrl which justifies alternative biburden specificatins that take the prduct manufacturing prcess int cnsideratin, in cntrast t defaulting t the histrical 10 CFU / 100 ml limit. This risk-based apprach cnsiders the tw main risks at the sterile filtratin step f drug prduct manufacture: (a) capability f the micrbilgical biburden methd and, (b) micrbial breakthrugh during sterile filtratin. These risks have been assessed fr their interactin by means f statistics and pssible risk-mitigating measures are described. Table f Cntents 1. Risk: the biburden determinatin methd Risk: Bacteria breakthrugh during sterile filtratin Cmbinatin f bth main risks The hlistic view cnsidering a prtfli f risk-mitigating measures Cnclusins References Addendum... 7 Page 1 f 12
2 1. Risk: the biburden determinatin methd As Jrnitz et al. (5) described, it is impssible due t the inherent variability f micrbilgical analyses, t determine an exact biburden in the rder f 10 CFU / 100 ml. The true biburden culd likely be belw r abve and thus the batch incrrectly accepted r falsely rejected. It is therefre mre accurate t specify the acceptable limit f 10 CFU plus a margin f errr. This inaccuracy in micrbilgical analyses is taken int accunt in USP Chapter <61> and als in the Ph.Eur. (Chapters and 5.1.4): an acceptance criterin fr micrbilgical quality f 10 CFU wuld therefre be crrespnding t a maximum acceptable cunt f 20 CFU when the variability f analysis is cnsidered. We have mdeled the sensitivity f the Ph.Eur biburden assay methd fr an acceptance criterin f 10 CFU / 100 ml (6) while varying the test sample vlume. The Pissn mdel assumes a unifrm distributin f the bacteria in the slutin prir t sterile filtratin and is therefre nt cnsidered a suitable mdel. Bacteria can clump tgether t prduce a nn-unifrm dispersin which leads t either verestimatin r underestimatin f detected biburden when determined by the number f cunts in the slutin. This ver-dispersin can be described by a negative binmial distributin with a crrespnding prbability density functin and an ver-dispersin factr. Based n a negative binmial mdel with an ver-dispersin factr f 2, it can be estimated that using a limit f 10 CFU / 100 ml, a slutin with a true biburden level f 10 CFU / 100 ml wuld have a 41.2% prbability f batch rejectin, althugh the specificatin wuld still be met. Cnversely, a true biburden f 11 CFU / 100 ml wuld still lead t a prbability f batch acceptance f 50% (see figure 2, Addendum). The prbability curve als demnstrates that - given an acceptable risk bund f 5% - a batch passing with a measured biburden f nt greater than 10 CFU/100 ml culd reveal a true biburden f up t 20 CFU/100 ml (fr a 100 ml test sampling plan). The prbability curve shifts t the right as the vlume tested decreases such that a 10 ml test vlume may have up t 63 CFU/100 ml actual biburden fr the same 5% prbability f false negatively passing and the same cntrl limit. This increase in acceptable actual biburden can be cmpensated by adjusting parameters fr Risk 2, as described in the next sectin. We cnclude that the specificatin f the biburden at the level 10 CFU / 100 ml is t tight, leading t unreasnably high rejectin prbability f acceptable batches. Furthermre, the micrbilgical quality f the slutin prir t sterile filtratin shuld be cnsidered hlistically and the ttal risk cmpsed f many individual risks shuld be cnsidered in rder t avid falsely accepting unacceptable batches due t the limited sensitivity f the test. 2. Risk: Bacteria breakthrugh during sterile filtratin Accrding t the FDA guideline (4) and industry standards, filters used fr the final filtratin shuld be validated t reprducibly remve micrrganisms frm a carrier slutin cntaining biburden f a high cncentratin f at least 10 7 CFU/cm 2 f effective filter area (EFA). The validatin shuld be cnducted under the wrst-case prductin cnditins fr the material t be filtered, and challenge experiments shuld result in n passage f the challenge micrrganism. Thus the retentin capacity f a validated sterilizing-grade filter with an EFA f A (cm 2 ) is at least A x 10 7 CFU. Hwever, the currently used 0.22 µm sterile filter membranes can withhld much higher micrbial challenges (unpublished cmpany results fr 0.22 µm plyvinylidene fluride membranes a bacterial challenge cncentratin as high as 10 9 CFU/cm 2 can be validated). In practice, accumulatin f biburden n the final filter might even cause partial clgging. As a result, a Page 2 f 12
3 biburden CFU that reaches the filter early in the prcess may have a higher prbability t penetrate the filter than thse that reach a partly clgged filter later in the prcess. Therefre it is cnservative t assume that all biburden CFUs in the slutin have the same prbability t g thrugh the final filter. Similar t terminal sterilizatin methds, fr sterile filtratin a Sterility Assurance Level (SAL = degree f assurance with which the prcess renders a ppulatin f items sterile) can be calculated based n the bacteria retentin capacity f the filter. Here, wrst case assumptins have been made, fr example during the validatin using a small micrrganism (typically Brevundimnas diminuta). Since the pre-sterile filtratin biburden is determined fr each lt and nt nly as part f a validatin prcedure, the SAL can als be calculated as a LOT-SPECIFIC parameter frm the actual, measured biburden lad (with a factr included fr variability), the applied ttal filter area and the validated effective bacteria retentin capability. Thus, the decisive factr f pre-filtratin biburden is knwn (within assay variability) and nt assumed. Fr prducts subjected t terminal sterilizatin, the true biburden is nt determined (the Draft EMA Guideline n the Sterilizatin f the Medicinal Prduct, Active Substance, Excipient and Primary Cntainer suggests a maximum biburden limit f 100 CFU / 100 ml r 100 g befre) as the manufacturing prcess des nt take place under aseptic cnditins, and this must be cmpensated by incrprating apprpriate safety factrs. Since the filling prcess is run under class C cnditins, a relatively high biburden must be assumed which then has t be killed by the terminal sterilizatin prcedure. In cntrast, the sterile filtratin prcess prir t aseptic filling can be cnsidered a clsed system, fllwed by manufacture under class A cnditins. Finally, the bacteria are mechanically retained instead f being inactivated, and therefre d nt enter the final prduct. In summary, fr sterilizatin f prduct thrugh sterile filters SAL values lwer than used fr terminal sterilizatin (<10-6 ) shuld be acceptable e.g r Cmbinatin f bth main risks The tw types f main risks assciated with the sterile filtratin prcess can be statistically described (6): Risk 1 ( pre-sterile filtratin risk ): risk due t biburden test methd insensitivity (risk f false negative = passing a batch with unacceptable biburden), i.e. the drug slutin with an unacceptable biburden level befre sterile filtratin passes the pre-sterile filtratin biburden test, either due t inherent test methd variability r a sampling methd that des nt have sufficient statistical pwer t detect drug slutins with unacceptable levels f biburden Risk 2 ( pst-sterile filtratin risk ): risk f breakthrugh f biburden thrugh the final sterile filter with 1 CFU entering the sterile filtered slutin due t an inapprpriate prcess, i.e. prcess-related risks and micrbial breach acrss sterile filter These tw risks are inter-dependent as a high pre-sterile filtratin risk wuld require a mre stringent cntrl f the pst-sterile filtratin risk and vice versa. Therefre an effective verall cntrl strategy shuld take int accunt this inter-crrelatin. Yang et al (6) linked maximum batch size, sample vlumes f 10 ml, 30 ml and 100 ml (negative binmial mdel, specificatin limit 10 CFU / 100 ml and acceptance limit f pre-filtratin biburden 1 CFU/10 ml, 3 CFU/30 ml, 10 CFU/100 ml) t the Risk 1 prbability f incrrectly accepting a batch (5%, 1% and Page 3 f 12
4 0.1%) and the Risk 2 prbability f a breakthrugh f 1 CFU in ne f 10,000 cases (0.01% prbability, 10-4 ) r 1 f 100,000 cases (0.001% prbability, 10-5 ). A validated bacterial retentin capability f the sterile filter f 10 7 CFU per cm 2 was used, fr a 1000 cm 2 filter, t calculate the maximum vlume t be sterile filtered. A mdified versin f the risks-linking table is attached t this psitin paper (see table 1, Addendum). By example, a 10 ml sample size using an actin limit f 1 CFU/10 ml, with a 5% risk f passing a batch thrugh a false negative result and a filter breakthrugh risk f 10-4, allws a maximum filtratin batch vlume f 424 L when using a 1000 cm 2 (0.1 m 2 ) filter. Nte that when e.g. δ 0 = 5% (pre-filtratin risk, i.e. risk f biburden testing insensitivity) and δ = 10-4 (pst-filtratin risk, i.e. breakthrugh risk f biburden thrugh the sterile filter), there is a 95% prbability that the pre-sterile filtratin biburden test (fr any given test scheme) will successfully detect unacceptable levels f biburden and nly 1 batch ut f 10,000 wuld have biburden breakthrugh (see Table 1). This implies that in a facility prducing 100 batches a year, this event wuld nly ccur every 100 years. By limiting the maximum filtered batch size, accepted pst-sterile filtratin risk levels can achieve the same level f sterility quality assurance, fr any given pst-filtratin risk (δ), as the biburden testing with 100 ml samples and a 10 CFU/100 ml acceptance limit. Indeed, it is prpsed that a Risk 1 prbability f 5% shuld be acceptable. Alternatively, t manipulating the filtratin batch size, ther parameters may als be varied t reduce risk, e.g. increasing filter area r validated maximum CFU. The relatinship between sample vlume and the batch size varies accrding t filter area, as illustrated in Figure 3 f the Addendum. A 10 ml sample size using a 1000 cm 2 filter allws up t 424 L t be filtered t retain a 5% prbability f passing a batch with biburden exceeding the acceptance limit and filter penetratin f less than 1 in 10,000 batches. Fr a 2000 cm 2 filter the filtered vlume culd be increased t 849 L at the same risk level (see table 1). The relatinship between filtratin batch size and filter area is tabulated and prvides the Spnsr with the pprtunity t select the sterile filtratin, minimum filter area accrding t filtratin batch size t prvide a desired level fr Risk 1 (0.1% t 5%) and Risk 2 (10-4 t 10-5 ). Therefre, fr a given risk bund, the pre-filtratin risk can be cntrlled with a prperly selected batch size r the pst-filtratin risk can be cntrlled thrugh filter area and filter validatin. The biburden level D 0 may be even greater than 10 CFU/100 ml since its impact n the final pst-filtratin risk can be cntrlled thrugh placing a limit n the size f a batch fr the sterile filtratin S 0 r adjusting the filter area r the validated range s as t ensure the ttal biburden in the batch wuld nt exceed the retentin capacity f the final sterilizing filter. The presented calculatins supprt use f biburden test sample vlumes 10 ml using a filter area f 1000 cm 2, a maximum filtratin batch size f 400 L and an actin limit f up t 2 CFU/10 ml that includes a 3-fld safety factr fr the biburden determinatin precisin (calculated frm 63 CFU / 100 ml). These limits ensure a pre-filtratin biburden risk f 5% and a pst-filtratin risk f Further risk mitigatin is built int the prduct manufacturing prcess as summarized in the next sectin. 4. The hlistic view cnsidering a prtfli f risk-mitigating measures Mitigating risk factrs are essential fr the final biburden risk assessment f the sterile filtratin prcess. This includes examinatin f the related prcess steps and understanding f the prduct characteristics and ptential prduct related risk factrs like viscsity, ph r grwth prmting prperties f the frmulatin. Fr example, if the frmulated prduct has grwth prmting prperties, this cnstitutes a risk factr per se. It is als imprtant t evaluate available biburden data, including the manufacturing facility histrical Page 4 f 12
5 biburden detectin trends fr the prduct and acrss prducts when a multi-prduct site is used. Histrical biburden trend data are ften indicative f the effectiveness f the verall biburden cntrl, and need t be cnsidered in identificatin f risk factrs. The fcus f this paper is n parenteral bitech drugs that cannt be terminally sterilized in the final cntainer because they are therm-labile. Fr such prducts, hwever, the testing f the biburden prir t sterile filtratin and the subsequent sterile filtratin are nt the nly measures t cntrl the micrbilgical status f the slutins fr cntainer filling (see figure 2, addendum): The upstream and dwnstream prcesses are likely t have multiple 0.2 micrn r nan-filtratin steps fr reductin f adventitius micrbial, particulates r viral cntaminatin. The fermentatin itself takes place in clsed systems subject t a CIP / SIP prcess and under the additin f filtered r HTST-treated r even sterile media. The final frmulatin steps are carried ut in a Grade C envirnment and als use steamdecntaminated r sterilized cntainers int which the slutin is being transferred via 0.2 micrn filter. In the event f extended strage f the frmulated slutin, strage is usually at lw temperatures, typically -20, -40 r -80 C. In the frzen state bacterial grwth is extremely unlikely. Interim strage in the liquid state is time-limited fr reasns f prduct stability alne and perfrmed mstly als at reduced temperatures (2 8 C), further bacterial grwth is hereby als limited. Strage and hld times f bulk after final frmulatin r thawing are evaluated in studies and eventually validated. Rm temperature strage is kept at a minimum. Mnitring the cntainer integrity during such interim strage is ften dne by superimpsing pressure (nitrgen). Furthermre, interim bulk strage after thawing may be (re-)validated using grwth-prmting media in rder t uncver micrbilgical weaknesses (as part f the regular media fills). Increasingly, upstream, dwnstream and fill/finish prcessing use pre-sterilized single-use materials and aseptic cnnectrs ( dispsables prcessing cmpnents ). These are ften surced preassembled as maniflds, pre-sterilized and aseptically cnnected. In additin, these cmpnents represent clsed systems, which reduce the risk f biburden entering by nn-aseptic cnnectins. Thrugh increasing autmatin f manufacturing prcesses, individual persnnel errrs are further mitigated. The cmmercially available sterile filters have a larger bacteria retentin capacity than the underlying minimum expectatin f 10 7 CFU / cm 2. Fr early clinical phase manufacture, the rati between filter surface area and batch size is typically relatively high cmpared t cmmercial scale manufacture. Endtxin cntent (in case e.g. pyrgens are prduced by biburden) and sterility testing is part f the Drug Prduct release prcess An analysis f data frm the cmpanies invlved in this paper has shwn that it is a very rare event t find biburden ver the limit set by the EMA befre the sterile filtratin. Often it is an artifact f sampling r in the analysis, but bth are each difficult t prve with 100% certainty, s finally the batch is ften still discarded which is very cstly and may endanger the prduct develpment timelines. Each biburden fund, even if belw the limit f 10 CFU / 100 ml may trigger identificatin f the micrbial cntaminant, s that regardless f a limit set, investigatin and crrective measures are initiated. Page 5 f 12
6 Fr this reasn, the authrs are f the pinin that the prcessing f bitechnlgical active ingredients is typically under ample cntrl fr biburden, which allws the determinatin and justificatin f lwer sample vlumes and wider pre-defined levels f biburden befre sterile filtratin, using risk-based strategies. 5. Cnclusins Bitechnlgy-derived drug prducts are typically labile t methds f terminal sterilizatin such as irradiatin, chemical treatment r autclaving, and are manufactured thrugh aseptic prcessing which typically emplys sterile filtratin t remve micrbial cntaminants. High biburden in the drug slutin prir t sterile filtratin may increase the chance f breaching the sterilizing filter and cause prduct safety and quality issues. As a result, pre-filtratin biburden test is recmmended by regulatry guidelines. The current EMA guidelines stipulate that a maximum acceptable biburden level must be established befre the sterile filtratin step and that in general n mre than 10 CFU/100 ml wuld be acceptable. Hwever, a sample vlume f 100 ml ften represents a significant prprtin f the batch and a high cst fr bitech prducts, particularly taking int accunt that sufficient material wuld typically be drawn fr replicate testing, assay cntrls, verage and reserve samples. Therefre it is desirable t explre alternate sample vlumes and test methds that warrant the same r higher level f quality assurance as the EMA-recmmended methd. The guidelines allw the Spnsr t justify alternative sampling prcedures thugh n guidance is prvided n what might cnstitute an acceptable justificatin. Furthermre, the EMA guidelines d nt prvide scientific ratinale fr limit 10 CFU/100 ml, thereby cmpunding the difficulty t justify a test vlume smaller than 100 ml r ther limits. In this paper, a risk-based methd is prpsed t prvide a strategy and scientific methdlgy fr justifying alternate (smaller) biburden test vlumes than 100 ml and alternate specificatins (>10 CFU/100 ml r >1CFU/10 ml).. By mdeling biburden in the slutin prir t sterile filtratin, the relatinship(s) between pre-sterile filtratin risk (prbability f detecting biburden in the slutin prir t sterile filtratin) and pst-sterile filtratin risk (prbability f biburden breaching the filter), their cmbined risk as well as the assciated risk factrs such as test sample vlume r batch size are established. Such relatinships allw fr quantitative evaluatin f the impact f the risk factrs n the develpment f effective risk-based cntrl strategies, which include acceptable selectin f sample test vlume and maximum pre-filtratin biburden level. The risk-based methd is in accrdance with the quality by design (QbD) principles in ICH Q8 that enable manufacturers t define a manufacturing prcess design space that cnsistently prduces high-quality prducts thrugh increased understanding and knwledge f the prduct and prcess. It is als cnsistent with ICH quality initiative, Quality Risk Management, which achieves prduct greater quality assurance thrugh risk identificatin, analysis, and cntrl. The risk-based apprach als justifies use f actin limits fr cntrl f the pre-sterile filtratin biburden limit thrugh implementatin f an effective Quality Management System (QMS) that describes the actins fllwed in the eventuality f any detected biburden. The cnditins that initiate investigatin f biburden, determinatin f likely rt cause and any resulting CAPA shuld be available t the agency and may be verified thrugh GMP inspectin. Spnsrs may als emply tighter internal criteria per the QMS. Ultimately, the agency shuld be assured that any batch with a significant biburden breach ptentially impacting prduct quality r safety wuld be rejected. The nus shuld remain with the Spnsr t determine the definitin f significant. Page 6 f 12
7 Key findings f the paper include: Pre-filtratin and pst-filtratin risks are inter-crrelated. A hlistic apprach needs t be taken in develpment f risk mitigatin strategies s that a seemingly high risk in ne prcess step can be mitigated thrugh cntrlling risk factrs in ther step. Risk factrs are inter-dependent and shuld be cnsidered jintly when evaluating their impact f the pre-filtratin and pst filtratin risks. This includes selectin f sample test vlume, acceptable biburden limits, sterilizing filter area, in an integrated assessment; A biburden level higher than 10 CFU/ 100 ml in the unfiltered drug slutin may nt incur unnecessary risk as its impact can be mitigated thrugh effective sterilizing filtratin; Sample vlumes less than 100 ml and acceptance limits different frm 10 CFU/100 ml can be justified, thrugh cntrlling ther risk factrs such as batch size r filter area, withut increasing the risk f biburden breakthrugh in the final filtratin; Testing f biburden prir t final filtratin and the sterile filtratin are nt the nly measures t cntrl the micrbial status and t generate sterile prduct. Hlistic cncepts may be established that reduce risks prir t the final biburden testing and the sterile filtratin. Enhanced understanding f the manufacturing prcess and prduct attributes is key t successful biburden risk management. 6. References 1. EMA (1996). CPMP Ntes fr Guidance n Manufacture f Finished Dsage Frm. 2. EMA (2012). EMA Guideline n the Requirements fr Quality Dcumentatin Cncerning Bilgical Investigatinal Medicinal Prducts in Clinical Trials. (EMA/CHMP/BWP/534898/2008), currently under revisin 3. Draft Guideline f EMA n the sterilizatin f the medicinal prduct, active substance, excipient and primary cntainer, April 11, U.S. FDA Guidance fr Industry: Sterile Drug Prducts Prduced by Aseptic Prcessing Current Gd Manufacturing Practice, Jrnitz MW, Akers JE, Agallc JP, Madsen RE, and Melzer TH (2003). Cnsideratins in sterile filtratin. Part II: the sterilizing filter and its rganism challenge: a critique f regulatry standards. PDA Jurnal f Pharmaceutical Science and Technlgy. March/April. Vl. 57, N. 2, p Yang H, Li N and Chang S (2013). A risk-based apprach t setting sterile filtratin biburden limits. PDA J. f Pharm. Science and Technlgy. Vl. 67: Addendum Manufacture f drug prducts (chemical synthesis r frm cell/micrbial cell cultures) generally fllw a similar set f prcess steps illustrated in Figure 1. Each f the nine steps includes cntrl f either biburden r sterility. They als include several filtratin and chrmatgraphic steps that may deplete any adventitius biburden frm the prduct. The prduct cntact prcess materials are cleaned and validated t minimize risk n cntaminatin. Page 7 f 12
8 Surce f material Material generated by bipharmaceutical prcess (prtein, Mab, DNA) N. f prcess step 1 Prcess Step Fermentatin Reductin/ cntrl f biburden Sterile cnditins (clsed systems, sterile feeds) Biburden checks Check fr freign rganisms 2 CFF (Cell free filtrate) after harvest Depth filtratin r Centrifugatin Pre- and pstfiltratin check 3 Purificatin (Catin exchange, Anin exchange, HIC, nanfiltratin, thers) Nanfiltratin, clumn resins trapping micrrganisms (+ cleaning cycles at unfavurable cnditins and validated re-use f clumns/ filter), qualified hld times Pre- and pstfiltratin checks Material generated by chemical synthesis (peptide, sirna, small mlecule) 4 Final Frmulatin after buffer exchange e.g. by UF/DF 0.2 micrn filtratin int sterilized cntainers, Class C envirnment Pre- and pstfiltratin check 5 DS strage cld r frzen in varius cntainers (bags, cryvessels, bttles, cans) Strage temperature slwing dwn r impeding micrbial grwth, qualified DS hld time (expiry) including biburden Biburden limit (specificatin) 6 Thawing f DS (if frzen) 0.2 micrn filtratin (ptinal), limited and qualifiied hld time (Pre- and) pst-filtratin check (ptinal) 7 Mixing/pling and dilutin/additin f excipients r full cmpunding Class C envirnment, 0.2 micrn filtratin (Pre-) and pstfiltratin check (ptinal) 8 Bulk fr sterile filtratin Limited and qualified hld time Pre-sterile filtratin check 9 Sterile Filtratin (inline during filling r ff-line befre filling) and dispensing int vials, syringes, cartridges etc. Sterile filtratin (ne r tw filters) Sterility check f final drug prduct and f sterile filtered bulk (if applicable) Figure 1. Typical prcess flw diagram fr manufacture f liquid bilgical drug prduct sterilised by filtratin. Page 8 f 12
9 Figure 2: Perfrmance characteristics f biburden testing using 100 ml samples and 10 CFU/100 ml acceptance limit, based n negative binmial distributin with a dispersin factr f 2 (6); dtted line: 5% acceptable risk bund. The Ph.Eur test fr biburden des nt have the capability t determine an accurate biburden cunt in a slutin as detectin depends n the vlume tested. The prbability f passing a batch fr biburden is best determined using a negative binmial distributin t accunt fr the clumping prperties f micrbes. Figure 2 illustrates such a prbability curve relatinship with the actual biburden level when 100 ml is tested. There is a significant prbability f failing and rejecting a gd batch r passing a bad batch n the basis f any single biburden test when cnsidered in islatin and applying an acceptance criterin f 10 CFU/100 ml. A hlistic apprach t biburden risk is recmmended that accmmdates the sterile filtratin prcess and assciated risk. Page 9 f 12
10 Figure 3: Design Space fr biburden test scheme (here: prbability f at least 1 CFU < 10-4 ) dependent n filtered vlume and filter area fllwing a risk-based apprach The relatinships demnstrate the breakthrugh risk fllwing biburden determinatin can be cntrlled thrugh the batch vlume filtered and/r filter area. The Spnsr may determine the biburden cntrl strategy that best fits the prcess and facility within the design space. A test sample vlume f 10 ml frm a 424 L filtratin batch size is illustrated (red circle) as acceptable when using a 1000 cm 2 filter. Page 10 f 12
Principle and Procedure of Analytical Test Method Validation for GMP Regulated Industry
Principle and Prcedure f Analytical Test Methd Validatin fr GMP Regulated Industry Regulatry Basis: FDA Quality Systems Regulatins Reference: FDA CFR - Cde f Federal Regulatins Title 21 Purpse The purpse
More informationBest Practices for Safety Action Review Boards
Best Practices fr Safety Actin Review Bards By Brian Hughes, Vice President f Slgic A versin f this article appeared in the May 2011 issue f Prfessinal Safety magazine. Many safety departments I wrk with
More informationUNC 0594R: Meter Reading Submission for Advanced & Smart Metering. UNC Request Workgroup Report
UNC Request Wrkgrup Reprt At what stage is this dcument in the prcess? UNC 0594R: Meter Reading Submissin fr Advanced & Smart Metering The rllut f Advanced and Smart Metering delivers the pprtunity t utilise
More informationAcceptance criteria for process capability indexes generated from statistical tolerance intervals as per ISO
Acceptance criteria fr prcess capability indexes generated frm statistical tlerance intervals as per Backgrund Justificatin fr sampling plans and statistical analysis f results is a requirement fr prcess
More informationVI. ALTERNATIVES TO THE MASTER PLAN A. INTRODUCTION
VI. ALTERNATIVES TO THE MASTER PLAN A. INTRODUCTION INTRODUCTION As stipulated in Sectin 21002.1(a) f the CEQA Statutes (Public Resurces Cde): The purpse f an envirnmental impact reprt is t identify the
More informationFlaw indications in the reactor pressure vessels of Doel 3 and Tihange 2
Flaw indicatins in the reactr pressure vessels f Del 3 and Tihange 2 1. Cntext Technical infrmatin nte 2013.02.01 Del 3 and Tihange 2 are tw f the seven Belgian nuclear reactrs perated by Electrabel, a
More informationCPA P2 Audit Practice & Assurance Services
TOPIC 28 MATERIALITY ISA 320 Materiality in Planning and Perfrming an Audit prvides guidance t auditrs in this area and states the bjective f the auditr is t apply the cncept f materiality apprpriately
More informationICH Q12 and reduction in post approval complexity Dr Frank Montgomery, Global Head, Reg CMC, AstraZeneca UK EFPIA Expert to ICH Q12 EWG
ICH Q12 and reductin in pst apprval cmplexity Dr Frank Mntgmery, Glbal Head, Reg CMC, AstraZeneca UK EFPIA Expert t ICH Q12 EWG Tpra 2017 Oct 2017 Disclaimer The views presented d nt necessarily reflect
More informationDown Under. Project Management Essential in Process Management Projects
A BPTrends Clumn Dwn Under December 2007 Jhn Jestn & Jhan Nelis BPM Cnsultants, Sydney Australia Authrs: Business Prcess Management Practical Guidelines t Successful Implementatins jhn.jestn@managementbyprcess.cm
More informationIBM Global Services. Server Optimization ... Trends and Value Proposition That Can Drive Efficiencies and Help Businesses Gain A Competitive Edge
IBM Glbal Services Server Optimizatin.......... Trends and Value Prpsitin That Can Drive Efficiencies and Help Businesses Gain A Cmpetitive Edge Intrductin A typical rganizatin s success and ability t
More information0XXX: Meter Reading Submission for Advanced & Smart Metering. Stage 01: Request
Stage 01: Request 0XXX: Meter Reading Submissin fr Advanced & Smart Metering At what stage is this dcument in the prcess? The rllut f Advanced and Smart Metering delivers the pprtunity t utilise mre frequent
More informationKootenai River Restoration Master Plan: Master Plan Overview
Ktenai River Restratin Master Plan: Master Plan Overview Ktenai River Restratin Prject #200200200 Restre Natural Recruitment Ktenai River White Sturgen Prject Overview In late 2006, the KTOI received prject
More informationCorporate Value Chain (Scope 3) Accounting & Reporting Standard. Summary of Changes
Nvember 2010 Wrld Business Cuncil fr Sustainable Develpment Crprate Value Chain (Scpe 3) Accunting & Reprting Standard Summary f Changes 1. Intrductin This dcument summarizes the changes made t the GHG
More informationGeneral principle on planning and design of Multi-Regional Clinical Trials
ICH E17 General principle n planning and design f Multi-Reginal Clinical Trials January 14th, 2017 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Pharmaceuticals fr Human Use Legal Ntice
More informationModule 10: Economics of Nutrient Management and Environmental Issues. To view the chapter for this topic click here.
Mdule 10: Ecnmics f Nutrient Management and Envirnmental Issues T view the chapter fr this tpic click here. Intrductin The bjective f nutrient management is t select the prper nutrient rate, placement,
More informationBirmingham Airport Response REDACTED (for external use)
The aim f the questins belw is t allw us t understand hw yu cnducted the recent pen tender prcesses. The questins frm a brad guide t ur areas f interest. We request that as well as either written r ral
More informationReport on Inspection of Grant Thornton LLP (Headquartered in Chicago, Illinois) Public Company Accounting Oversight Board
1666 K Street, N.W. Washingtn, DC 20006 Telephne: (202) 207-9100 Facsimile: (202) 862-8433 www.pcabus.rg Reprt n 2013 (Headquartered in Chicag, Illinis) Issued by the Public Cmpany Accunting Oversight
More informationAvoiding Microbiological Media Related Failures
Micrrite, Inc. brings yu this unique learning experience in Aviding Micrbilgical Media Related Failures; Part f Micrrite s step-by-step webinar series. Aviding Micrbilgical Media Related Failures Reprting
More informationPanel Project Solicitation
Panel Prject Slicitatin April 4, 2016 BUSINESS PROCESSES ELECTRICAL TECHNOLOGIES ENVIRONMENTAL INFORMATION TECHNOLOGIES PLANNING, PRODUCTION PROCESSES & FACILITIES RISK MANAGEMENT SHIP DESIGN & MATERIAL
More informationNEW FERTILIZER REGULATION
www.fertilizerseurpe.cm www.prductstewardship.eu www.danfertilizers.cm NEW FERTILIZER REGULATION POSITION OF FERTILIZERS EUROPE ON PRESENTATION AND COMMENTS MADE BY DG ENTERPRISE ON ESSENTIAL SAFETY AND
More informationDesign Alternatives Sheet: The Objective Function in Capacity Market Clearing
Design Alternatives Sheet: The Objective Functin in Capacity Market Clearing 1.1 What is the bjective functin when ptimizing the auctin clearing? Maximizing Scial Surplus Typically, the market clearing
More informationForward Steps in the Generic ADF Lifecycle
Frward Steps in the Generic ADF Lifecycle 1 BACKGROUND Generic prducts nw accunt fr 89% f US prescriptins As new abuse deterrent frmulatins are apprved fr brand prducts, there shuld be apprpriate FDA guidance
More informationIMI2 PROPOSAL TEMPLATE FIRST STAGE PROPOSAL
IMI2 PROPOSAL TEMPLATE FIRST STAGE PROPOSAL IN TWO-STAGE PROCEDURE (TECHNICAL ANNEX) RESEARCH AND INNOVATION ACTIONS & INNOVATION ACTIONS Nte: This is fr infrmatin nly. The definitive template fr yur call
More informationIESBA Meeting (November/December 2015) Long Association Proposed Changes to Section 290 (MARK-UP from ED)
IESBA Meeting (Nvember/December 2015) Agenda Item 5-B General Prvisins Lng Assciatin Prpsed Changes t Sectin 290 (MARK-UP frm ED) 290.148A Familiarity and self-interest threats, which may impact an individual
More information5.2 RPM Auction Timeline
5.2 RPM Auctin Timeline The fllwing Auctin timeline prvides the deadline fr key RPM activities: RPM Activity Submittal f preliminary request t remve resurce frm Capacity Resurce status and preliminary
More information5.2 RPM Auction Timeline
5.2 RPM Auctin Timeline The fllwing Auctin timeline prvides the deadline fr key RPM activities: RPM Activity Submittal f preliminary request t remve resurce frm Capacity Resurce status and preliminary
More informationECNG Energy Group. Performance Review Plan
ECNG Energy Grup Perfrmance Review Plan Cntents Overview 3 Summary 3 Purpse 3 Key Phases and Timelines 4 1) Perfrmance Planning: Start f Q1 4 Setting Individual Objectives 5 2) Onging Caching and Mid-year
More informationAn Experiment on the Electric Energy Performance of the Wind Turbine Rotors
Jurnal f Applied Sciences 4 (1): 144-148, 2004 ISSN 1607-8926 2004 Asian Netwrk fr Scientific Infrmatin An Experiment n the Electric Energy Perfrmance f the Wind Turbine Rtrs Ali Vardar and Bülent Eker
More informationManual 11: Energy & Ancillary Services Market Operations Revision History
2.3.4 Minimum Generatr Operating Parameters Parameter Limited Schedules Belw is the list f business rules t require units t submit schedules that meet minimum accepted parameters. Market Sellers are required
More informationRegulations Amending the Food and Drug Regulations (1475 Good Manufacturing Practices)
Canada Gazette: Vl. 147, N. 10 May 8, 2013 Registratin SOR/2013-74 April 26, 2013 FOOD AND DRUGS ACT Regulatins Amending the Fd and Drug Regulatins (1475 Gd Manufacturing Practices) P.C. 2013-420 April
More informationTotal RNA from Whole Blood, Plasma & Serum
H A N D B O O K Ttal RNA frm Whle Bld, Plasma & Serum NP-0201R 50 Preps Genetix Bitech Asia Pvt. Ltd. 71/1, First Flr, Shivaji Marg, Najafgarh Rad, New Delhi - 110015 Phne : +91-11-45027000 n Fax : +91-11-25419631
More informationDigital Advisory Services Professional Service Description Software Defined Networking Strategy and Roadmap
Digital Advisry Services Prfessinal Service Descriptin Sftware Defined Netwrking Strategy and Radmap 1. Descriptin f Services. 1.1 Sftware Defined Netwrking Strategy and Radmap. Verizn will prvide Sftware
More informationCountry profiles: Iceland
Cuntry prfiles: Iceland Last updated: 26/06/2015 1 Implementatin f Tracking Systems 1.1 Electricity Disclsure Electricity disclsure in Iceland is implemented by Regulatin number 757/2012, Regulatin n disclsure
More informationBelgian Building Research Institute. Lightweight self-compacting concrete with Argex aggregates
Belgian Building Research Institute Lightweight self-cmpacting cncrete with Argex aggregates 1. Intrductin and prject bjective: This dcument is a shrt verview f the research prject entitled Lightweight
More informationEMISSION REDUCTIONS UNDER CAP-AND-TRADE PROPOSALS IN
EMISSION REDUCTIONS UNDER CAP-AND-TRADE PROPOSALS IN THE 111 TH CONGRESS Jhn Larsen and Rbert Heilmayr June 25, 2009 This analysis prvides an assessment f reductins in greenhuse gas (GHG) emissins relative
More informationConducting a Risk Assessment for Non-Sterile Facilities E-Workshop
Micrrite, Inc. brings yu this unique learning experience in Cnducting a Risk Assessment fr Nn-Sterile Facilities; Part f Micrrite s step-by-step E-Wrkshp series. Cnducting a Risk Assessment fr Nn-Sterile
More informationCity of Vancouver Planning By-law Administration Bulletins
City f Vancuver Planning By-law Administratin Bulletins Planning, Urban Design and Sustainability Department 453 West 12th Avenue, Vancuver, BC V5Y 1V4 tel: 3-1-1, utside Vancuver 604.873.7000 fax: 604.873.7100
More informationITIL FOUNDATION SUMMARY NOTES. Sessions
ITIL FOUNDATION SUMMARY NOTES Sessins 2 Service Management as a Practice 2 3 Service Lifecycle 3 4 Service Strategy 4 5 Service Design 5 6 Service Transitin 6 7 Service Operatin 7 8 Cntinual Service Imprvement
More informationCDM Plan Submission and Review Criteria Rules
Cnservatin First Framewrk LDC Tl Kit Final v4.0 January 17, 2018 CDM Plan Submissin and Review Rules 1) Purpse and definitins 1.1 These Rules set ut: a) the rles, respnsibilities and timing fr CDM Plan
More informationFront end GUI automation ROI: a changing definition
Frnt end GUI autmatin ROI: a changing definitin Capgemini India Private Limited July 2013 Prepared by: Angshuman Dutta 1 Table f Cntents 1. Abstract...2 2. Autmatin ROI backgrund...2 2.1 Traditinal expectatins...
More informationMethod 1: Establish a rating scale for each criterion. Some options are:
Decisin Matrix Als called: Pugh matrix, decisin grid, selectin matrix r grid, prblem matrix, prblem selectin matrix, pprtunity analysis, slutin matrix, criteria rating frm, criteria-based matrix. Descriptin
More informationProject Measurement and Verification Procedures
Prject Measurement and Verificatin Prcedures 1) Intrductin The bjective f measurement and verificatin (M&V) activities at the Prject level is t cnfirm that the Measures that are supprted by the Efficiency:
More informationREMI - Outline performance and technical specifications
REfurbishment as Manufacturing Industry REMI Prject 24 May 2016 REMI - Outline perfrmance and technical specificatins WP2.2 - WP3.1 Deliverable Intrductin The cncept f deep retrfit is nt new. The main
More informationReregistration of voluntarily deregistered CDM project activities
Paragraph 4 f the anntated agenda, Annex 1 Reregistratin f vluntarily deregistered CDM prject activities CDM EB 87 Paris, France, 23 27 Nvember 2015 UNFCCC Secretariat SDM prgramme Prcedural backgrund
More informationNotes and guidance: Paper 1 Section B Poetic voices
Ntes and guidance: Paper 1 Sectin B Petic vices This resurce explains hw the questin in the specimen assessment materials fr AS Paper 1, Sectin B, Petic vices, addresses the assessment bjectives, with
More informationReport on Inspection of PricewaterhouseCoopers LLP (Headquartered in New York, New York) Public Company Accounting Oversight Board
1666 K Street, N.W. Washingtn, DC 20006 Telephne: (202) 207-9100 Facsimile: (202) 862-8433 www.pcabus.rg Reprt n 2014 (Headquartered in New Yrk, New Yrk) Issued by the Public Cmpany Accunting Oversight
More informationCAPIEL Position Paper - RoHS Scope
CAPIEL Psitin Paper - RHS Scpe 1 - Purpse f this paper The purpse f this CAPIEL paper is t help manufacturers t determine whether r nt the prducts they place n the market fall within the scpe f the recast
More informationNanogate Jay Systems
Nangate Jay Systems Revisin: H Page 1 1.0 Purpse The purpse f this prcedure is t prvide fr a system and instructins t give each supplier the necessary tls t prvide prduct and services that meet the expectatins
More informationNEW APPROACHES TO CONTROL WALNUT BLIGHT. Milton Schroth, Joe osgood, Bill Olson, Art McCain, Mavis Chong, John Bahme, and Yang-An Lee.
NEW APPROACHES TO CONTROL WALNUT BLIGHT December, 1988 Miltn Schrth, Je sgd, Bill Olsn, Art McCain, Mavis Chng, Jhn Bahme, and Yang-An Lee. ABSTRACT Last year's research prpsal presented a three year prgram
More informationParenteral Filling Facility Automation Case Study. Shawn Hull, Avid Solutions JV Cotterell, Eisai Inc
Parenteral Filling Facility Autmatin Case Study Shawn Hull, Avid Slutins JV Ctterell, Eisai Inc System Overview Greenfield Parenteral Filling facility with tw filling lines (Cmmercial Line and Clinical
More informationAdvancing Tools and Processes for Next Generation Science Model B: Planning for Instruction
HO 1 Advancing Tls and Prcesses fr Next Generatin Science Mdel B: Planning fr Instructin Cpyright BSCS 2018 1 Five Tls and Prcesses fr NGSS Mdel B: Tl 1: Using the NGSS t Plan a Unit f Instructin HO 2
More informationMIS The Expert System Expert System Development
Expert System (ES) An Expert System (ES) is a knwledge based infrmatin system that uses its knwledge abut a specific, cmplex applicatin area t act as an expert cnsultant t end users. Expert system prvides
More informationThe Core Team Process: Making Risk-Informed Decisions for On-site Monitoring at the SRS
The Cre Team Prcess: Making Risk-Infrmed Decisins fr On-site Mnitring at the SRS Mary A. Flra Directr, Envirnmental Cmpliance & Area Cmpletin Prjects Savannah River Nuclear Slutins, LLC January 10, 2014
More informationDATE FOR COMING INTO EFFECT 1 April 2014*
Lndn, 24 March 2014 EMA/14522/2007-Rev.1 The Revised Checking Prcess f Mck-Ups and Specimens f uter/immediate labelling and package leaflets in the Centralised Prcedure fr Veterinary Medicinal Prducts
More informationAIM BRIEFING PAPER CONSIGNMENT STOCK APRIL 2011 ASSOCIATION DES INDUSTRIES DE MARQUE EUROPEAN BRANDS ASSOCIATION EUROPÄISCHER MARKENVERBAND
ASSOCIATION DES INDUSTRIES DE MARQUE EUROPEAN BRANDS ASSOCIATION EUROPÄISCHER MARKENVERBAND AIM BRIEFING PAPER CONSIGNMENT STOCK APRIL 2011 9 AVENUE DES GAULOIS B-1040 BRUSSELS BELGIUM TEL +322 7360305
More informationWeek 1 Introduction to Management Accounting:
Week 1 Intrductin t Management Accunting: Objective #1: What is management accunting?! Accunting Infrmatin System: the prcess f gathering, rganising and cmmunicating financial infrmatin.! Management Accunting:
More informationCustomer best practices
Custmer dcument Custmer best practices Recmmendatins fr new Basware transactin services custmers Basware Crpratin Cpyright Basware Crpratin All rights reserved 1 (11) 1 Intrductin Our best advice This
More informationFREQUENTLY ASKED QUESTIONS REMEDIATION TECHNOLOGIES WORKSHOP
FREQUENTLY ASKED QUESTIONS REMEDIATION TECHNOLOGIES WORKSHOP Objectives Q1. What are the bjectives f the Remediatin Technlgies prjects? A1. Kuwait Oil Cmpany is cmmitted t a sustainable remediatin slutin
More informationGiovanni Migliaccio Head, Section of Gene and Cell Therapy Istituto Superiore di Sanità
REGULATION (EC) N 1394/2007 Advanced Therapy Medicinal Prducts Givanni Migliacci Head, Sectin f Gene and Cell Therapy Istitut Superire di Sanità Rme Italy REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE
More informationSTAFF REPORT. Peter Zielsdorf
STAFF REPORT Applicatin: Cnstruct a new septic drainfield t replace the existing drainfield apprximately 64 feet frm Mink Lake (min. 75 ft required). Applicant: Agenda Item: 4(a) Peter Zielsdrf Backgrund
More informationIdentifying and Analysing Flow
Identifying and Analysing Flw 12 th 15 th Octber 2015 Lean Enterprise Academy, Rss n Wye, UK Thrugh instructin, small grup discussins and exercises, the wrkshp participants will learn abut the 3 levels
More informationAnnex D: The development of access and participation targets
Annex D: The develpment f access and participatin targets Backgrund 1. English higher educatin prviders have made steady prgress t imprve access and participatin ver the past decade, but there is still
More informationInquiry processing. 1. Purpose. 2. Scope. 3. Description
1. Purpse T describe the assessment f inquiry dssiers submitted t ECHA accrding t Article 26(1) f the REACH Regulatin and the steps taken t ensure that the data sharing amng ptential and previus registrants
More informationCommunications White Paper
Intrductin The quality and effectiveness f the cmmunicatin between the prject and the stakehlder grups is a significant cntributing factr t prject success r failure. Cmmunicatin is abut sending and receiving
More informationIESBA Meeting (March 2013) Agenda Item
Agenda Item 7-A Backgrund Lng Assciatin f Senir Persnnel (Including Partner Rtatin) with an Audit Client Matters fr Cnsideratin 1. Paragraph 290.150 f the IESBA Cde f Ethics fr Prfessinal Accuntants (the
More informationGuidance notes for completing the International Start-up Form
Guidance ntes fr cmpleting the Internatinal Start-up Frm These guidance ntes are designed t supprt yu in cmpleting the Internatinal start-up frm. Yu will als need t refer t a) yur Stage 2 applicatin frm
More informationITEM 10a: WAKE COUNTY HYBRID STORMWATER DESIGN TOOL SUBMITTAL JORDAN LAKE NUTRIANT STRATEGY COMPLIANCE SUBMITTAL SEPTEMBER 10, 2011
ITEM 10a: WAKE COUNTY HYBRID STORMWATER DESIGN TOOL SUBMITTAL JORDAN LAKE NUTRIANT STRATEGY COMPLIANCE SUBMITTAL SEPTEMBER 10, 2011 Wake Cunty Hybrid Tl Wake Cunty is unique in that it has its wn vlume
More informationPrinciples for Sound Stress Testing Practices and Supervision
P1.T4. Valuatin & Risk Mdels Principles fr Sund Stress Testing Practices and Supervisin Binic Turtle FRM Study Ntes By David Harper, CFA FRM CIPM www.binicturtle.cm Principles fr Sund Stress Testing Practices
More informationImprove Threshold Values Tuning of Transaction Monitoring Systems by Taking a Qualitative Approach
Imprve Threshld Values Tuning f Transactin Mnitring Systems by Taking a Qualitative Apprach Issue Central t any transactin mnitring system are the threshld values at which each f the selected transactin
More informationDirection for simplification and streamlining of the CDM
Directin fr simplificatin and streamlining f the CDM CDM EB 84 Bnn, Germany, 25 28 May 2015 UNFCCC Secretariat SDM prgramme Prcedural backgrund (1) The Bard, at EB 82, cnsidered the cncept nte n simplificatin
More informationSend questions to:
Send questins t: BPI.Seminars@prpelmg.cm GPure Prepacked Clumns A high-perfrmance, flexible purificatin platfrm Rick Garretsn Business Develpment Manger 3 GPure Prepacked Clumns Delivering flexibility
More informationVEHICLE MILES TRAVELED (VMT)
DATE: April 13, 2017 TO: FROM: RE: San Francisc Planning Department Transprtatin Cnsultants Wade Wietgrefe, Senir Planner In September 2016, a memrandum was sent t the transprtatin cnsultant pl regarding
More informationHOUSING NEED AND DEMAND STUDY
HOUSING NEED AND DEMAND STUDY (Dcument Template) March 2010 Intrductin: BC Husing cnsiders the needs f all municipalities in the Prvince during deliberatins n the lcatin f new affrdable husing prjects.
More informationEnd of Year Planning and Checklists
TechnlgyOne Financials End f Year Planning End f Year Planning and Checklists This dcument prvides checklists and discussin pints fr sme f the main Technlgy One mdules. The TechnlgyOne Supprt Centre knwledge
More informationIn this fact sheet we answer the four most common questions new clients ask:
Wrking With Federal Prpsals Intrductin In this fact sheet we answer the fur mst cmmn questins new clients ask: What tasks d yu perfrm and what d yu need frm us? Hw d we use the Virtual War Rms? Hw much
More informationOn-line estimation of colour, turbidity and ph values in sugar refining process
Indian Jurnal f Engineering & Materials Sciences Vl. 3, June 1996, pp. 96-100 On-line estimatin f clur, turbidity and values in sugar refining prcess R Gvindaraj & P E Sankaranarayanan Ccnual Hccunic-,
More informationWorking Families Success Network in Community Colleges Definitions and Expected Design Elements
Wrking Families Success Netwrk in Cmmunity Clleges Definitins and Expected Design Elements Cre Prgram and Service Delivery Elements Clleges shuld prvide services in each f the three WFSNCC cre pillars:
More informationTime is Money Profiting from Reduced Cycle Time
Time is Mney Prfiting frm Reduced Cycle Time Yur retail custmers are demanding smaller, mre frequent shipments, which increases yur cst-t-serve them. While this makes their inventry mre predictable and
More informationOPTIMIZE. Core Banking System Replacement. OPTIMIZE Advisory Note. The Issues. Key Recommendations
Building a Business Case fr Cre Banking Systems Renewal Mark Flynn, 7 th Feb 2012 DcID: 122105028 The Issues Cre banking system replacement is the mst challenging IT prjects that a Bank can face. Such
More informationKNOWLEDGE CAPTURE INTERVIEW
Inter-American Develpment Bank KNOWLEDGE AND LEARNING SECTOR (KNL) TECHNICAL NOTES KNOWLEDGE CAPTURE INTERVIEW N. IDB-TN-424 June 2012 KNOWLEDGE CAPTURE INTERVIEW Inter-American Develpment Bank 2012 http://www.iadb.rg
More informationDRAFT Sampling Protocol For the LEED Canada for Homes Program Applicable to production builders (Balloted Version)
DRAFT Sampling Prtcl Fr the LEED Canada fr Hmes Prgram Applicable t prductin builders (Ballted Versin) This dcument prvides guidance n using the Sampling Prtcl t verify LEED Hmes. It includes infrmatin
More informationGenerally, in order to qualify for this exemption, a compounded drug must meet the following requirements:
In its May 4, 2015 FDB Custmer Cnnectin, First Databank (FDB) annunced a decisin t remve CutisPharma s cmpunding kits frm FDB s MedKnwledge Database as f June 8, 2015. We believe FDB s actins are ill-cnsidered,
More informationUser Applied Labelling of Injectable Medicines, Fluids and Lines Policy
Department f Health and Human Services SYSTEM PURCHASING AND PERFORMANCE - MEDICATION STRATEGY AND REFORM User Applied Labelling f Injectable Medicines, Fluids and Lines Plicy SDMS Id Number: Effective
More informationEffective Date: 21 Aug 2018 Issued: 06 Aug 2018 Issue: 3 SI No: P3282 Prepared: K. Osborne. Reviewed by: G. Ostacchini
Page 1 f 11 Effective Date: 21 Aug 2018 Issued: 06 Aug 2018 Issue: 3 SI N: P3282 Prepared: K. Osbrne Reviewed by: G. Ostacchini Apprved by: M. Sanders Date: 06 Aug 2018 (DD/MMM/YYYY) Title: Device Technical
More informationPredicting Successes and Failures of Clinical Trials
Predicting Successes and Failures f Clinical Trials Alex Ivliev, PhD Principal Scientist May 2018 2 Intrductin Despite imprvements acrss all stages f drug develpment, the rate f drug attritin due t clinical
More informationApplication Portfolio Analysis: Tool for Cloud Migration Dr. Gopala Krishna Behera December 5, 2017
Applicatin Prtfli Analysis: Tl fr Clud Migratin Dr. Gpala Krishna Behera December 5, 2017 Tday, a majrity f custmers are getting ut f the data center business and mving twards the use f Clud Services.
More informationSample Cytotoxicity Assay Protocol
Sample Cyttxicity Assay Prtcl Plating (Example) Day 1: Plate cells at 2500 cells/well fr a typical 3- plate cyttxicity assay: Cells shuld be lifted frm the flask (if need be) and cunted. Only the center
More informationWeb InfoPLU$ Account Transfer USER GUIDE
Web InfPLU$ Accunt Transfer USER GUIDE Fr infrmatinal purpses nly, nt cnsidered an advertisement. Web InfPLU$ Accunt Transfer USER GUIDE TABLE OF CONTENTS ACCOUNT TRANSFER... 2 ACCOUNT TRANSFER SUMMARY...
More informationHEALTH AND SAFETY POLICY MISSION STATEMENT
HEALTH AND SAFETY POLICY MISSION STATEMENT IPLOCA is ttally cmmitted t the prmtin f health and safety in all areas f its influence and subscribes t the philsphy that all accidents are preventable. Therefre
More informationHEALTH AND SAFETY POLICY MISSION STATEMENT
HEALTH AND SAFETY POLICY MISSION STATEMENT IPLOCA is ttally cmmitted t the prmtin f health and safety in all areas f its influence and subscribes t the philsphy that all accidents are preventable. Therefre
More informationPRINCIPLES OF PRTR AND AER REPORTING OF ANNUAL ENVIRONMENTAL INFORMATION
ENVIRONMENTAL PROTECTION AGENCY AER / PRTR GUIDANCE DOCUMENT N. 1: PRINCIPLES OF PRTR AND AER REPORTING OF ANNUAL ENVIRONMENTAL INFORMATION Fr use in reprting f: 1 PRTR Emissins and Waste Transfers infrmatin
More informationCORE INVENTORY MANAGEMENT
RSM TECHNOLOGY ACADEMY Syllabus and Agenda CORE INVENTORY MANAGEMENT FOR MICROSOFT DYNAMICS AX Curse Details 3 Audience 3 At Curse Cmpletin 3 Curse Cancellatin Plicy 4 Guaranteed t Run 4 Travel Guide 6
More informationTaking the Stress out of the FDA s UDI Labelling Regulations
Taking the Stress ut f the FDA s UDI Labelling Regulatins With the applicatin f the FDA s final ruling n medical devices Unique Device Identificatin (UDI) system in September 2013 there are nw new regulatins
More informationThis particular role is accountable for the development and implementation of an electronic Permit To Work (eptw) system.
Psitin Descriptin Prject Lead Created: 4 July 2017 Grup: Custmer Delivery Psitin number: TBA Jb family: Strategy and Gvernance Hurs wrked per week: As required Manager s title: Prgram Manager Manager nce
More informationNZATD Education Trust Awards elearning Award Guidelines for Entrants
NZATD Educatin Trust Awards elearning Award Guidelines fr Entrants Fcus f Award NZATD intrduced this award t recgnise excellence in the design and implementatin f elearning initiatives within rganisatins.
More informationDirectives 90/385/EEC and 93/42/EEC MEDICAL DEVICES. Clinical Evaluation Report Presentation guide
Directives 90/385/EEC and 93/42/EEC MEDICAL DEVICES Clinical Evaluatin Reprt Presentatin guide The elements f the clinical evaluatin reprt are recrds f the prcess that the manufacturer applies t the identificatin,
More informationHeat Pump KEYMARK. Date Description of modification Revision number Initial version 1
Page: 1 f 26 Date Descriptin f mdificatin Revisin number 14-12-2015 Initial versin 1 10/03/2017 Additin f air/air Editrial changes Annex E included in reference t pren12102-2 suppressed Reference t EN
More informationGuidance on the Privacy and Electronic Communications (EC Directive) Regulations
Infrmatin Security Guidance Title: Status: Guidance n the Privacy and Electrnic Cmmunicatins (EC Directive) Regulatins Released 1. Purpse This guidance n the Privacy and Electrnic Cmmunicatins (EC Directive)
More informationinemi Statement of Work (SOW) NEMI Board Assembly TIG inemi Functional Test Coverage Assessment Project
inemi Statement f Wrk (SOW) NEMI Bard Assembly TIG inemi Functinal Test Cverage Assessment Prject Versin # 1 Date 2-20-07 Prject Leader: C-Prject Leader: TC Cach: Page 1 f 8 Basic Prject Infrmatin Purpse:
More informationINTERCEPT SURVEY DATA GUIDE JUNE Visitor/Shopper Intercept Survey Data Guide
Visitr/Shpper Intercept Survey Data Guide June 26, 2014 Table f Cntents 1 Intrductin... 3 1.1 Timeline... 3 1.2 Availability f Data... 3 2 Overview... 4 2.1 Summary f Cntents... 4 2.2 Data Dictinary...
More information